Development of emerging disease agent biologics

The development of emerging infectious disease biologics is essential for the advancement of One Health. The AVMA supports the development of these products through cooperation among researchers, biotechnology and animal health industries, and regulatory agencies. This includes, but is not limited to, sharing strains, sequences, reagents, and other components; publishing safety and efficacy data; removing barriers for access to intellectual property; and providing for accelerated pathways for regulatory approval.

Related policy